Cardiology

• 1. Introduction

  ›

  Cardiology sits at the center of medicine's most urgent business: keeping the heart beating. Cardiovascular disease is the leading cause of death in the United States, and in 2008 it accounted for nearly 25% of all deaths in the country. In 2013, coronary artery disease alone killed 8.14 million people worldwide, representing 16.8% of all global deaths. These numbers point to a field under enormous pressure, one that has had to grow far beyond a single discipline into a constellation of subspecialties, each targeting a different way the heart can fail. What makes cardiology both intellectually demanding and structurally unusual is how sharply it divides along lines of age, mechanism, and method. An adult cardiologist cannot simply step in to treat a child's heart, and a surgeon and a cardiologist, though they often work on the same organ, practice entirely different trades. How did cardiology become this complex? And who built it?

• 2. How the Field Is Divided

  ›

  Werner Forssmann performed the first human cardiac catheterization on himself, a move so controversial it got him fired from the Berliner Charité Hospital and drove him out of cardiology entirely. He later won the 1956 Nobel Prize in Physiology or Medicine for that same act. That arc, a procedure considered reckless becoming the foundation of an entire subspecialty, captures how interventional cardiology was born.

  Today, interventional cardiologists use catheterization routinely. A sheath is inserted into the femoral artery or radial artery and threaded through the vascular system under X-ray guidance, most commonly fluoroscopy. If a blockage is found, a balloon on the catheter tip is inflated to compress the plaque against the vessel wall, and a stent is placed to hold the artery open permanently. Primary angioplasty performed this way is now the gold standard of care for an acute myocardial infarction. A key advantage over open surgery is the avoidance of the chest incision, the scar, and the long post-operative recovery.

  Despite that overlap, surgery and cardiology remain formally separate. Coronary artery bypass surgery and surgical valve replacement belong to cardiothoracic surgeons. Cardiologists identify who needs those procedures and refer them onward. An increasing number of structural repairs, however, have migrated into the catheter-based world, including transcatheter aortic valve implantation (TAVR), the MitraClip device for mitral valve repair, and ablation procedures for heart rhythm disorders.

• 3. The Electrical Heart

  ›

  Willem Einthoven built the first practical electrocardiogram and won the 1924 Nobel Prize in Physiology or Medicine for discovering the mechanism behind it. That single instrument, the ECG or EKG, became the foundation of an entire subspecialty: cardiac electrophysiology.

  The heart's electrical system is centered on the sinoatrial node, the cardiac pacemaker that triggers each contraction. Action potentials travel through the electrical conduction system in a specific pattern. When that pattern breaks down, the results range from the relatively minor to the catastrophic. Wolff-Parkinson-White syndrome, ventricular fibrillation, and heart block are among the conditions that arise when the electrical system misfires.

  Electrophysiologists study and treat these rhythm disorders using invasive catheter recordings of the heart's spontaneous electrical activity, as well as programmed electrical stimulation. Their goal is often to assess the likelihood that a patient will develop potentially fatal sustained ventricular tachycardia or ventricular fibrillation. Treatments include radiofrequency ablation, cryoablation, antiarrhythmic drug therapy, and implantation of pacemakers and automatic implantable cardioverter-defibrillators. Reaching that level of practice takes eight years of post-medical-school training in the United States: three years of internal medicine residency, three years of cardiology fellowship, and two years of clinical cardiac electrophysiology.

  Atrial fibrillation alone affected about 2% to 3% of the population in Europe and North America as of 2014. Atrial fibrillation and atrial flutter together resulted in 112,000 deaths in 2013, up sharply from 29,000 in 1990. Sudden cardiac death accounts for about half of all cardiovascular deaths globally, and roughly 80% of those cases trace back to ventricular arrhythmias.

• 4. Helen Taussig and the Blue Babies

  ›

  Helen B. Taussig, born in 1898, is recognized as the founder of pediatric cardiology. Her defining work centered on a congenital heart defect called Tetralogy of Fallot, the most common congenital heart disease, arising in 1 to 3 cases per 1,000 births. The condition involves a ventricular septal defect and an overriding aorta, which together allow deoxygenated blood to bypass the lungs and re-enter the circulatory system. Newborns with the defect develop a bluish tint, known as cyanosis, and a deficit of oxygen in their tissues, hypoxemia.

  Taussig worked with surgeon Alfred Blalock and technician Vivien Thomas at Johns Hopkins Hospital. They experimented on dogs, studying how to surgically redirect blood flow, and eventually solved the problem through anastomosis: connecting the systemic artery to the pulmonary artery. The resulting procedure was named the Blalock-Taussig Shunt. The modern version, the modified Blalock-Taussig shunt, places a graft between the subclavian artery and the ipsilateral pulmonary artery.

  Taussig died in 1986. Her work opened a field that would eventually have to confront an unanticipated downstream problem: the patients she helped survive into childhood began surviving into adulthood. As more children with congenital heart disease reached adult life, a hybrid discipline called adult congenital heart disease (ACHD) emerged. It can be entered from either the adult or the pediatric cardiology pathway, and it addresses congenital conditions in the presence of adult diseases such as coronary artery disease, COPD, and diabetes, a combination that is otherwise atypical for either branch.

• 5. Coronary Artery Disease and Its Numbers

  ›

  Coronary artery disease was the most common cause of death globally in 2013. The mechanism is atherosclerosis: fatty plaques narrow the coronary arteries, the vessels that supply oxygen-rich blood to the heart muscle itself. Because the coronary arteries are classified as end circulation, meaning they are the only blood supply to the myocardium with very little redundancy, even a partial blockage can cause angina, and a complete one can trigger a heart attack.

  In the United States in 2010, about 20% of people over 65 had coronary artery disease. Among those aged 45 to 64, the rate was 7%, and among those aged 18 to 45, it was 1.3%. Rates are higher in men than in women of the same age. Despite those prevalence numbers, the risk of dying from the disease for a given age fell between 1980 and 2010, particularly in developed countries, and the number of cases for a given age also declined between 1990 and 2010.

  Prevention overlaps heavily with treatment: a healthy diet, regular exercise, weight control, and not smoking are recommended in both contexts. Medications may include antiplatelets such as aspirin, beta blockers, and nitroglycerin. For severe disease, percutaneous coronary intervention or coronary artery bypass surgery are the main procedural options. The ISCHEMIA trial, published in 2020, found that medical therapy is as good as coronary stents in stable coronary artery disease, a finding that shifted how cardiologists think about when to intervene.

• 6. Training Pathways Around the World

  ›

  Per Doximity, adult cardiologists in the United States earn an average of $436,849 per year. Reaching that point takes a minimum of six years after medical school: a three-year internal medicine residency followed by a three-year cardiology fellowship. Further sub-specialization in areas recognized by the Accreditation Council for Graduate Medical Education, including clinical cardiac electrophysiology, interventional cardiology, adult congenital heart disease, and advanced heart failure and transplant cardiology, adds more years on top.

  In the United Kingdom, the path runs differently. After two years of foundation training and three years of internal medicine training, doctors enter a five-year cardiology specialty training programme. Before they can begin specialty training, they must hold the Membership of the Royal Colleges of Physicians of the United Kingdom diploma. The programme ends with a Certificate of Completion of Training in cardiology.

  In India, the full journey from finishing secondary school to becoming a cardiologist takes around 11.5 years. Students take the National Eligibility cum Entrance Test (NEET-UG), complete an MBBS course lasting 5.5 years including an internship, pass either the NEET-PG or INI-CET exam, complete three years of MD study in General Medicine, and then complete a three-year DM in cardiology. Pediatric cardiologists in the United States follow a parallel track: a three-year pediatrics residency followed by a three-year pediatric cardiology fellowship, with the Doximity data placing their average salary at $303,917.

• 7. Landmark Trials That Changed Practice

  ›

  Cardiology is known for randomized controlled trials that carry enough weight to shift how entire conditions are treated. The ISIS-2 trial in 1988 established the use of aspirin in myocardial infarction. The CAST trial in 1991 produced a counterintuitive result: antiarrhythmic agents given after a heart attack actually increased mortality, overturning what had seemed a logical approach. That same year, the SOLVD trial showed that ACE inhibitors benefit patients with heart failure, a finding whose physiological basis had been established earlier by Edmund Sonnenblick, who proved through research that the heart behaves as a muscle.

  The 4S trial in 1994 demonstrated that statins reduce the risk of heart disease. The MIRACLE trial in 2002 showed the benefit of cardiac resynchronization therapy in heart failure. SCD-HeFT in 2005 established the implantable cardioverter-defibrillator as a life-saving intervention in heart failure patients. Bernard Lown, who lived from 1921 to 2021, was the original developer of the defibrillator that made those devices possible.

  More recently, the RELY trial in 2009 and the ROCKET-AF and ARISTOTLE trials in 2011 supported replacing warfarin with direct oral anticoagulants in atrial fibrillation. PARADIGM-HF in 2014 introduced angiotensin-neprilysin inhibitors as a heart failure treatment. The EMPEROR-Preserved trial in 2021 identified a role for SGLT2 receptor agents in heart failure, a drug class originally developed for diabetes. The WHO reports that 37% of all premature deaths globally are due to cardiovascular diseases, with 82% of those occurring in low and middle income countries, giving every one of these trials a reach that extends far beyond the hospitals where they were conducted.